Deerfield Management Company, L.P. (Series C) Biomea Fusion, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $93,794 - $221,878	11,206 New	11,206 $162,000
Q3 2021 Nov 15, 2021	SELL	$10.0 - $15.99 $2.48 Million - $3.97 Million	-248,447 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$13.65 - $20.93 $3.39 Million - $5.2 Million	248,447 New	248,447 $3.88 Million

Others Institutions Holding BMEA

# of Institutions

104

Shares Held

17.8M

Call Options Held

1.68M

Put Options Held

410K

Cormorant Asset Management, LP Boston, MA

3.57M
Shares

$22.4 Million
2.53% of portfolio
Black Rock Inc. New York, NY

2.34M
Shares

$14.7 Million
0.0% of portfolio
Baker Bros. Advisors LP New York, NY

2.11M
Shares

$13.2 Million
0.23% of portfolio
Vanguard Group Inc Valley Forge, PA

1.4M
Shares

$8.78 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

1.38M
Shares

$8.66 Million
0.01% of portfolio

View Full List

About Biomea Fusion, Inc.

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $184M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

More about BMEA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account